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Original Article
Purpose: We reviewed treatment outcomes and prognostic factors for patients with salivary ductal carcinoma (SDC) treated with 
surgery and postoperative radiotherapy from 2005 to 2012.
Materials and Methods: A total of 16 patients were identified and 15 eligible patients were included in analysis. Median age 
was 61 years (range, 40 to 71 years) and 12 patients (80%) were men. Twelve patients (80%) had a tumor in the parotid gland, 9 
(60%) had T3 or T4 disease, and 9 (60%) had positive nodal disease. All patients underwent surgery and postoperative radiotherapy. 
Postoperative radiotherapy was delivered using 3-dimensional conformal radiotherapy or intensity-modulated radiotherapy. 
Locoregional failure-free survival (LRFFS), distant failure-free survival (DFFS), progression-free survival (PFS), and overall survival (OS) 
were calculated using the Kaplan-Meier method. Differences in survival based on risk factors were tested using a log-rank test.
Results: Median total radiotherapy dose was 60 Gy (range, 52.5 to 63.6 Gy). Four patients received concurrent weekly 
chemotherapy with cisplatin. Among 10 patients who underwent surgery with neck dissection, 7 received modified radical neck 
dissection. With a median follow-up time of 38 months (range, 24 to 105 months), 4-year rates were 86% for LRFFS, 51% for DFFS, 
46% for PFS, and 93% for OS. Local failure was observed in 2 patients (13%), and distant failure was observed in 7 (47%). The lung 
was the most common involved site of distant metastasis.
Conclusion: Surgery and postoperative radiotherapy in SDC patients resulted in good local control, but high distant metastasis 
remained a major challenge.
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Introduction
Salivary gland cancers represent 3%–6% of all head and 
neck cancers in adults [1]. Salivary duct carcinoma (SDC) 
is a rare type of salivary gland cancer and is recognized as 
an aggressive malignancy. Because it is rare, no prospective 
studies on SDC have been published and only a few 
retrospective reports on 10 to 50 patients are available [2-5]. 
In Korea, previous research has included a retrospective study 
of 35 patients treated with surgery and adjuvant postoperative 
radiotherapy and case reports of patients with SDC [6-10].
  SDC occurs mainly in the parotid gland and has poor 
prognosis and frequent local and distant failures. According to 
some reports, most patients with SDC die within three years 
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[1,4]. Five-year overall survivals are reported to be 42% for 
stage I, 40% for stage II, 30% for stage III, and 23% for stage 
IV disease [4]. In a review of literature by Hosal et al. [3], local 
recurrence was experienced by 15%–55% of patients and 
distant metastasis by 33%–62%. 
  Because of the rarity of the disease, results regarding the 
treatment of SDC are limited. This report is a retrospective 
study of SDC patients at a single institution in Korea who were 
treated with surgery and postoperative radiotherapy. 
Materials and Methods
1. Patient eligibility and characteristics
A retrospective analysis of all patients with SDC was performed 
at our institution. A list of SDC patients between January 
2005 and December 2012 from an institutional cancer registry 
identified 16 patients. Patients who had salivary gland surgery 
and histologically proven SDC were included in analysis. All 
patients received postoperative radiotherapy; patients who 
failed to finish scheduled radiotherapy were excluded. We 
excluded 1 patient who received 16.2 Gy of radiotherapy 
because patients who fail to finish the scheduled radiotherapy 
were excluded from analysis. He received salvage re-irradiation 
after recurrence in postoperative tumor bed and successfully 
achieved disease control, but lung metastasis occurred later.
  Of the 16 patients identified, 15 eligible patients were 
analyzed. The characteristics of the 15 patients are in Table 1. 
The median age was 61 years (range, 40 to 71 years) with 13 
(87%) older than 50 years, and 12 patients (80%) were men. 
Twelve patients (80%) had a tumor in the parotid gland, 2 
(13%) in the submandibular gland, and 1 (7%) in the maxillary 
sinus. Nine patients (60%) had T3 or T4 disease, and 9 (60%) 
had positive nodal disease. Seven patients (44%) had a positive 
resection margin, 8 (62%) had perineural invasion, 5 (42%) 
had lymphovascular invasion, and 6 (38%) had extracapsular 
extension of metastatic lymph nodes. 
2. Pretreatment evaluation
Pretreatment evaluation included a complete history and 
physical examination. Laboratory studies included a complete 
blood cell count and serum chemistry profile. For stage workup, 
patients underwent imaging studies, such as computed 
tomography (CT) and/or magnetic resonance imaging (MRI). 
Positron emission tomography, whole body bone scans, and 
chest CT were performed for systemic evaluation. 
3. Treatment details
Patients received surgery and postoperative radiotherapy. 
Postoperative radiotherapy was administered after wound 
recovery from surgery using ≥6 MV photons generated by a 
linear accelerator. Either 3-dimensional conformal radiotherapy 
(3D-CRT) or intensity-modulated radiotherapy (IMRT) was 
used. Contrast-enhanced CT simulation with thermoplastic 
device was mandatory and a mouthpiece to remove the 
tongue from the radiation field was used according to the 
radiation oncologist’s preference. Gross tumor volume (GTV) 
included residual tumor volume and metastatic lymph nodes. 
Clinical target volume (CTV) was defined as GTV plus a 2-cm 
margin or postoperative tumor bed plus a 1-cm margin and 
encompassed the elective nodal area. In all patients, elective 
nodal irradiation (ENI) target volume was the nodal areas of 
the operated neck including level II, level III, and level IV neck 
nodes. We used 3D-CRT, multifield technique, and cone-down 
technique. Total radiation dose was 63 Gy if the patient had 
risk factors, such as gross residual tumor or extracapsular 
extension of metastatic lymph nodes; if a patient had no risk 
Table 1. Patient characteristics and pathologic features
Characteristic No. of patients (%)
Age (yr), median (range)
    ≤50
    >50
Gender
    Male
    Female
Site
    Parotid gland
    Submandibular gland
    Maxillary sinus
T stage
    T1
    T2
    T3
    T4
N stage
    N0
    N+
Pathologic features
    Positive resection margin
    PNI
    LVI
    ECE
61 (40–71)
2 (13.0)
13 (87.0)
12 (80.0)
3 (20.0)
12 (80.0)
2 (13.0)
1 (7.0)
4 (27.0)
2 (13.0)
8 (53.0)
1 (7.0)
6 (40.0)
9 (60.0)
7 (44.0)
8 (62.0)
5 (42.0)
6 (38.0)
PNI, perineural invasion; LVI, lymphovascular invasion; ECE, ext-
racapsular extension.
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factors, the total radiation dose was 59.4 Gy. For N0 patients, 
after a dose of 45 Gy in 25 fractions, CTV was reduced to the 
postoperative tumor bed plus a 1-cm margin and ENI of level 
II and level III to deliver an additional boost dose of 14.4 Gy. 
Using IMRT, a simultaneously integrated boost technique 
was used so the GTV received a dose of 2.12 Gy per fraction. 
CTV1 encompassed the elective nodal area of level II and 
level III received 1.8 Gy per fraction; CTV2 encompassed the 
elective nodal area of level IV and received 1.7 Gy per fraction. 
The total fraction number of IMRT was 30. Total doses were 
63.6 Gy for GTV, 54 Gy for CTV1, and 51 Gy for CTV2. Total 
IMRT dose was similar to total dose of 3D-CRT in biologically 
equivalent doses. CTV was modified to reduce the dose to 
organs at risk, such as the spinal cord, optic apparatus (optic 
nerves and chiasm), mandible, pharynx, larynx, and esophagus. 
The maximal dose constraints were below 45 Gy for the spinal 
cord, below 55 Gy for the optic apparatus, and below 70 Gy for 
the mandible. Other organs at risk, such as the larynx, pharynx, 
and esophagus, were also delineated and set for doses as low 
as possible. For the planning target volume, a 0.3-cm margin 
was applied to the CTV considering patient motion and daily 
setup error.
  Four patients received concurrent weekly chemotherapy of 
cisplatin (40 mg/m2). One patient aged 70 years received a 
dose of 25 mg/m2 because he had poor general performance 
status. Cisplatin was administered on day 1. Indications of 
chemotherapy were gross residual tumor, positive resection 
margin, and extracapsular extension of metastatic lymph 
nodes. After scheduled postoperative radiotherapy, no adjuvant 
chemotherapy was given. 
4. Follow-up and response assessment
Each patient was examined weekly to monitor treatment-
related toxicities through all phases of treatment or more often 
if clinically indicated. After radiotherapy completion, patients 
visited the hospital every 3 months for the first 2 years, every 
6 months for the next 3 years, and annually thereafter. Follow-
up studies consisted of blood tests including complete blood 
count, serum chemistry profile, and imaging studies, such 
as MRI or CT to assess treatment response. Response was 
evaluated using the Response Evaluation Criteria in Solid 
Tumors after completion of the therapy. Acute toxicities were 
recorded according to the National Cancer Institute’s Common 
Toxicity Criteria ver. 3.0. 
  Local failure was defined as increase in size of the residual 
tumor or a new lesion in the postoperative tumor bed, or 
failure in the radiation field. Regional failure was defined as 
the occurrence of a new lesion in the regional lymph node 
area or soft tissues adjacent to the nodal area. Distant failure 
was defined as metastatic lesion in distant organs, such as the 
lung, mediastinum lymph node, or brain.
5. Statistical analysis
All statistical analysis used SPSS ver. 20.0 (IBM, Armonk, NY, 
USA). Locoregional failure-free survival (LRFFS), distant failure-
free survival (DFFS), progression-free survival (PFS), and overall 
survival (OS) were calculated from the date of diagnosis to 
the event and were plotted using the Kaplan-Meier method. 
Differences in survival between risk factors were tested using 
a log-rank test. A p-value <0.05 was considered statistically 
significant. 
Results
1. Treatment characteristics
Treatment characteristics of patients are summarized in 
Table 2. Median total radiotherapy dose was 60 Gy (range, 
52.5 to 63.6 Gy) and median fractional dose was 1.8 Gy 
(range, 1.8 to 2.25 Gy). All patients received postoperative 
tumor bed irradiation and elective nodal irradiation of level 
II, III, IV; 11 patients (73%) were treated with unilateral neck 
irradiation and 4 (27%) were treated with bilateral neck 
irradiation. Total resection of the primary site was performed 
Table 2. Treatment characteristics
Treatment No. of patients (%)
Radiotherapy
    Total dose (Gy), median (range)
    Fraction dose (Gy), median (range)
    Elective nodal irradiation
        Unilateral neck
        Bilateral neck
Surgery
    Resection of primary site
        Yes
        No
    Neck dissection
        Yes
        No
    CCRT
        Yes
        No
60 (52.5–63.6)
1.8 (1.8–2.25)
15 (100)
11 (73.0)
4 (27.0)
12 (80.0)
3 (20.0)
10 (67.0)
5 (33.0)
4 (27.0)
11 (73.0)
CCRT, concurrent chemoradiotherapy.
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for 12 patients (80%), and 3 patients (20%) underwent 
tumor resection only. Neck dissection was done for 10 
patients (63%) and 4 (25%) underwent weekly cisplatin-
based concurrent chemoradiotherapy. Of 10 patients with 
neck dissection, 7 received modified radical neck dissection, 
2 had supraomohyoid neck dissection, and 1 had lateral neck 
dissection.
2. Survival analysis
The median follow-up time was 38 months (range, 24 to 
105 months) for all patients and 38 months (range, 25 to 
105 months) for patients who were still alive at the time of 
analysis. Fig. 1 shows survival analysis for SDC patients. Four-
year rates were 86% for LRFFS, 51% for DFFS, 46% for PFS, 
and 93% for OS. 
3. Patterns of failure and risk factors for survival and 
toxicity
Patterns of failure are in Fig. 2. Local failure was observed for 
2 patients (13%), and distant failure was observed for 7 (47%). 
In contrast to the relatively high rate of distant failure, local 
or regional failure was less common. Of 2 patients who had 
local failure, one had SDC at the parotid gland and received 
total parotidectomy. Pathologic stage was pT3N0M0 with 
positive perineural invasion. The patient had supra-auricular 
skin recurrence at 8 months after postoperative radiotherapy, 
apparently within the radiotherapy field. Retrospective review 
of the radiation field indicated that the radiation dose to the 
Fig. 1. Kaplan-Meier overall survival (OS, A), progression-free survival (PFS, B), locoregional failure-free survival (LRFFS, C), and distant 
failure-free survival (DFFS, D) curves.
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superficial skin was insufficient. After wide resection of the 
skin at the recurrent disease and ear covering with an anterior 
lateral thigh flap, the patient recovered and had no evidence 
of disease at last follow-up. Another patient who initially 
had a tumor at the left parotid gland with pathologic stage 
pT3N2bM0, perineural invasion, lymphovascular invasion, 
and extracapsular extension of metastatic lymph nodes 
experienced local recurrence in the internal auditory canal. 
Recurrent disease at the internal auditory canal occurred just 
outside the border of the radiotherapy field. The patient had 
synchronous local and distant failure with lung metastasis. 
Although salvage re-irradiation was attempted, the patient 
died from lung metastasis progression. Table 3 shows distant 
failure sites. The lung was the most commonly involved distant 
metastasis site.
  Risk factors for survival are summarized in Table 4. Positive 
resection margin showed only a trend toward improved 
PFS (71% vs. 15%, p = 0.071). Only 2 patients had distant 
metastasis with positive resection margins, whereas 2 had local 
failures and 4 had distant metastases with negative resection 
margin. Age, sex, T stage, N stage, perineural invasion, 
lymphovascular invasion, extracapsular extension, radical 
surgery, concurrent chemoradiotherapy, and radiotherapy dose 
were not associated with LRFFS, DMFS, PFS, or OS.
  No grade 3 or 4 acute toxicities were observed. The most 
frequent toxicities were grade 2 oral mucositis and grade 2 
radiation dermatitis.
Discussion and Conclusion
SDC was first described by Kleinsasser and his colleagues in 
1968. SDC is a high-grade tumor and occurs at the ductal 
epithelium of the salivary gland. Histologically, SDC is 
indistinguishable from ductal carcinoma of the breast [11]. 
The standard treat ment for SDC is surgical resection with 
postoperative radiotherapy. However, many investigators 
noted that distant metastasis is a major clinical problem and 
most patients die from disseminated disease. Hosal et al. [3] 
Fig. 2. Patterns of failure.
Table 3. Sites of distant metastasis
Site No. of patients (%)
Lung
Mediastinal lymph node
Brain
Liver
5 (50.0)
2 (20.0)
2 (20.0)
1 (10.0)
Table 4. Risk factors for survival
Variable
4-yr LRFFS 
(%)
p-value
4-yr DMFS 
(%)
p-value 4-yr PFS (%) p-value 4-yr OS (%) p-value
Age (>50 yr)
Male gender
Early T stage (T1-2)
Nodal involvement
RM+
PNI
LVI
ECE
Radical surgery
CCRT
RT dose (≥60 Gy)
  83/100
  82/100
100/75
  88/83
100/71
  71/100
  80/80
  80/89
  89/80
100/82
  78/100
0.555
0.449
0.205
0.788
0.141
0.266
0.937
0.705
0.614
0.449
0.277
58/0
43/67
50/47
38/56
71/19
27/25
40/0
42/50
45/40
67/42
49/42
0.290
0.559
0.987
0.361
0.158
0.526
0.511
0.731
0.695
0.491
0.520
51/0
37/67
50/38
38/44
71/15
22/25
40/0
42/42
45/30
67/36
42/42
0.447
0.416
0.735
0.745
0.071
0.821
0.221
0.996
0.785
0.365
0.779
  73/100
  75/100
  83/67
  53/100
  80/75
  38/100
  50/67
  67/83
  63/100
100/75
  80/75
0.589
0.724
0.728
0.147
0.982
0.225
0.221
0.372
0.265
0.724
0.982
LRFFS, locoregional failure-free survival; DMFS, distant metastasis-free survival; PFS, progression-free survival; OS, overall survival; RM, 
resection margin; PNI, perineural invasion; LVI, lymphovascular invasion; ECE, extracapsular extension; CCRT, concurrent chemoradio-
therapy; RT, radiotherapy.
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reported that 43% of patients experience distant metastasis 
and 21% experience local recurrence after surgery and 
postoperative radiotherapy. Brandwein et al. [12] reported 
that 54% of patients experience distant metastasis and 45% 
experience local recurrence. Guzzo et al. [13] reported that, 
with combined surgery and radiotherapy, 65% of patients 
achieve local-regional control, but 46% experience distant 
failures. Our results showing 14% local recurrence and 53% 
distant metastasis were comparable to other studies, and 
our patients showed durable local-regional control. However, 
high rates of distant metastasis are inevitable with current 
management.
  Considering that SDC is a very rare tumor, only limited 
data are available on its biological behavior and immuno-
histochemical characteristics. Molecular studies show 
frequent overexpression of human epidermal growth factor 
receptor 2 (HER2) [14]. Because of the high incidence of HER2 
overexpression, some studies reported on trastuzumab-based 
therapy for in SDC. Nabili et al. [15] reported that, of 7 patients 
with HER2-positive SDC, 3 demonstrated a good response to 
chemotherapy in combination with trastuzumab. Perissinotti 
et al. [2] studied the role of trastuzumab in SDC management, 
and showed that high-risk patients receiving trastuzumab-
based chemotherapy had no tumor recurrence. We could not 
perform further investigations on molecular markers, such as 
HER2, because our study was retrospective.
  Our study had limitations of retrospective study design and 
a small number of patients. Because of these limitations, we 
could not find risk factors that were statistically significant. 
Kim et al. [10] reported that lymphovascular invasion and 
perineural invasion are significant prognostic factors for 
SDC. We showed only a trend for improved PFS with positive 
resection margins. As tumors with positive resection margins 
after surgery tend to easily recur, our results seemed to be 
unusual. We reviewed the relationship between radiation dose 
and resection margin and target volume. No total radiation 
dose differences were seen in CTV between patients with 
positive resection margins and negative resection margins. 
However for target volume, wide generous margins were 
applied to patients with positive resection margins. Patients 
who were treated with generous margins because of positive 
resection margins experienced no local failures, but patients 
with negative resection margins experienced 2 local failures. 
No studies have reported an adequate target volume for 
radiotherapy for SDC patients. According to Shinoto et al. [16], 
for patients with positive perineural invasion, CTV of involved 
cranial nerves and corresponding parts of the skull base was 
appropriate. In our study, CTV did not include involved cranial 
nerves or corresponding parts of the skull base. One patient 
had local recurrence in the internal auditory canal. Since he 
had positive perineural invasion, local control was achieved 
with CTV that included the involved cranial nerve. In addition, 
no patients had regional nodal failure when treated with 
elective nodal irradiation. The appropriate target volume for 
postoperative radiotherapy should be investigated for SDC. 
  Our findings showed very favorable results for locoregional 
control when treating SDC patients with surgery and 
postoperative radiotherapy. Based on our results and evidence 
from other reports, distant metastasis remains a major 
challenge of this aggressive disease. Further investigation is 
needed to explore effective systemic treatments for patients 
with high risk factors for distant metastasis. 
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